Grants per year
Personal profile
Training Experience
| 2004 | Postdoctoral Fellowship, Harvard Medical School |
| 2005 | Internship, Brigham & Women's Hospital |
| 2008 | Residency, Washington University Medical Center |
| 2012 | Residency, Cedars-Sinai Medical Center |
| 2013 | Fellowship, University of Michigan |
| 2014 | Fellowship, University of Michigan |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Business Administration, MBA, Indiana University
… → 2019
MD, Shahid Beheshti University, Tehran, Iran
… → 1999
Research interests
- Blood Cancer (leukemia and lymphomas)
- Molecular Diagnostics
- Molecular Genetics
- Non-Hodgkin's Lymphoma
- Oncology
Fingerprint
Dive into the research topics where Amir Behdad is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 1 Active
-
Liquid Biopsy to Measure Novel Biomarkers of ImmunoMetabolic Cancer Risk (IMCR)
Thaxton, C. S., Abaza, Y., Altman, J. K., Behdad, A. & Griffith, J. W.
V Foundation for Cancer Research
8/1/22 → 8/1/25
Project: Research project
-
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients
Zak, T., Gao, J., Behdad, A., Mehta, J., Altman, J. K., Ji, P., Lu, X. & Sukhanova, M., 2022, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Article › peer-review
-
Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide–coated nanoparticles
Lin, A. Y., Choi, B., Sim, T., Yang, E., Choi, H., Behdad, A., Kim, D. H. & Gordon, L. I., Aug 9 2022, In: Blood Advances. 6, 15, p. 4581-4592 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers
Shah, A. N., Sunderraj, A., Finkelman, B., See, S. H., Davis, A. A., Gerratana, L., Wehbe, F., Katam, N., Mahalingam, D., Gradishar, W. J., Behdad, A., Blanco, L. & Cristofanilli, M., 2022, In: Oncotarget. 13, 1, p. 273-280 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype
Tariq, H., Barnea Slonim, L., Coty Fattal, Z., Alikhan, M. B., Segal, J., Gurbuxani, S., Helenowski, I. B., Zhang, H., Sukhanova, M., Lu, X., Altman, J. K., Chen, Q. C. & Behdad, A., Jun 2022, In: British Journal of Haematology. 197, 6, p. 736-744 9 p.Research output: Contribution to journal › Article › peer-review
-
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
Pearse, W. B., Petrich, A. M., Gordon, L. I., Karmali, R., Winter, J. N., Ma, S., Kaplan, J. B., Behdad, A., Klein, A., Jovanovic, B., Helenowski, I., Smith, S. M., Evens, A. M. & Pro, B., 2021, In: Leukemia and Lymphoma. 62, 14, p. 3493-3500 8 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations